AP3391A - 2-Amino-4-arylthiazole compounds as TROA1 antagonists - Google Patents
2-Amino-4-arylthiazole compounds as TROA1 antagonistsInfo
- Publication number
- AP3391A AP3391A AP2013006906A AP2013006906A AP3391A AP 3391 A AP3391 A AP 3391A AP 2013006906 A AP2013006906 A AP 2013006906A AP 2013006906 A AP2013006906 A AP 2013006906A AP 3391 A AP3391 A AP 3391A
- Authority
- AP
- ARIPO
- Prior art keywords
- troa1
- antagonists
- amino
- arylthiazole compounds
- arylthiazole
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3451MU2010 | 2010-12-20 | ||
US201061428327P | 2010-12-30 | 2010-12-30 | |
IN748MU2011 | 2011-03-16 | ||
US201161466535P | 2011-03-23 | 2011-03-23 | |
IN1569MU2011 | 2011-05-25 | ||
US201161495002P | 2011-06-09 | 2011-06-09 | |
IN2741MU2011 | 2011-09-28 | ||
US201161552076P | 2011-10-27 | 2011-10-27 | |
PCT/IB2011/003224 WO2012085662A1 (en) | 2010-12-20 | 2011-12-15 | 2-amino-4-arylthiazole compounds as trpa1 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2013006906A0 AP2013006906A0 (en) | 2013-06-30 |
AP3391A true AP3391A (en) | 2015-08-31 |
Family
ID=46235162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2013006906A AP3391A (en) | 2010-12-20 | 2011-12-15 | 2-Amino-4-arylthiazole compounds as TROA1 antagonists |
Country Status (20)
Country | Link |
---|---|
US (3) | US8592398B2 (es) |
EP (1) | EP2655377B1 (es) |
JP (1) | JP5694560B2 (es) |
KR (1) | KR101591153B1 (es) |
CN (1) | CN103261201B (es) |
AP (1) | AP3391A (es) |
AR (1) | AR084294A1 (es) |
AU (1) | AU2011346763B2 (es) |
BR (1) | BR112013014692A2 (es) |
CA (1) | CA2820448A1 (es) |
CL (1) | CL2013001810A1 (es) |
EA (1) | EA023141B1 (es) |
HK (1) | HK1191008A1 (es) |
MX (1) | MX336549B (es) |
MY (1) | MY159059A (es) |
PE (1) | PE20140234A1 (es) |
SG (1) | SG191173A1 (es) |
TW (1) | TWI515199B (es) |
UA (1) | UA109916C2 (es) |
WO (1) | WO2012085662A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8969353B2 (en) | 2008-11-07 | 2015-03-03 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
UA109916C2 (uk) | 2010-12-20 | 2015-10-26 | Гленмарк Фармасьютікалс С.А. | 2-аміно-4-арилтіазольні сполуки як антагоністи trра1 |
WO2013023102A1 (en) | 2011-08-09 | 2013-02-14 | Hydra Biosciences, Inc. | Inhibiting transient receptor potential ion channel trpa1 |
NZ747501A (en) | 2011-10-27 | 2020-05-29 | Massachusetts Inst Technology | Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres |
WO2013108857A1 (ja) | 2012-01-17 | 2013-07-25 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
CA2873570C (en) | 2012-06-08 | 2016-11-01 | Glenmark Pharmaceuticals S.A. | Amides of 2-amino-4-arylthiazole compounds and their salts as trpa1 modulators |
PL2903965T3 (pl) | 2012-10-01 | 2017-08-31 | Orion Corporation | Pochodne n-prop-2-ynylokarboksamidu i ich zastosowanie jako antagonistów trpa1 |
US9394308B2 (en) | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
JP2016537322A (ja) * | 2013-10-15 | 2016-12-01 | グレンマーク ファーマシューティカルズ, エセ.アー. | Trpa1アンタゴニスト及び鎮痛剤を含む医薬組成物 |
EP3110453A4 (en) | 2014-02-24 | 2017-09-27 | The Johns Hopkins University | Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions |
RS64331B1 (sr) | 2015-06-19 | 2023-08-31 | Massachusetts Inst Technology | Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta |
FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
CN108727400B (zh) * | 2017-05-24 | 2021-07-09 | 四川晶华生物科技有限公司 | 一种治疗肿瘤的化合物 |
US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
CA3117213A1 (en) * | 2018-10-23 | 2020-04-30 | George Edward Hoag | Composition and method for treating the lungs |
MX2022004565A (es) * | 2019-10-15 | 2022-05-06 | Boehringer Ingelheim Int | Tienopirimidonas como inhibidores de trpa1. |
BR112022003729A2 (pt) | 2019-10-15 | 2022-05-31 | Boehringer Ingelheim Int | Tienopirimidonas como inibidores de trpa1 |
CA3180979A1 (en) * | 2020-04-22 | 2021-10-28 | George Edward Hoag | Method for treating viral and bacterial infection through inhalation therapy |
CN111437275B (zh) * | 2020-05-14 | 2021-03-19 | 黑龙江中医药大学 | 一种用于外科手术后抗炎和镇痛的药物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010109287A1 (en) * | 2009-03-23 | 2010-09-30 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as trpa1 modulators |
WO2010125469A1 (en) * | 2009-04-29 | 2010-11-04 | Glenmark Pharmaceuticals, S.A. | Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG160211A1 (en) | 2003-04-03 | 2010-04-29 | Semafore Pharmaceuticals Inc | Pi-3 kinase inhibitor prodrugs |
TW200720264A (en) * | 2005-04-25 | 2007-06-01 | Lundbeck & Co As H | Pro-drugs of n-thiazol-2-yl-benzamide derivatives |
CN101384261B (zh) | 2005-12-22 | 2011-12-07 | 海德拉生物科学公司 | 治疗疼痛的组合物 |
AU2008268463B2 (en) * | 2007-06-22 | 2015-03-05 | Eli Lilly And Company | Methods and compositions for treating disorders |
WO2009118596A2 (en) | 2008-03-26 | 2009-10-01 | Glenmark Pharmaceuticals, S. A. | Phthalimide derivatives as trpa1 modulators |
WO2009144548A1 (en) | 2008-05-28 | 2009-12-03 | Glenmark Pharmaceuticals S.A. | Imidazo [2,1-b] purine derivatives as trpa1 modulators |
WO2010004390A1 (en) | 2008-06-17 | 2010-01-14 | Glenmark Pharmaceuticals, S.A. | Quinazoline dione derivatives as trpa1 modulators |
WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
TW201026700A (en) | 2008-12-22 | 2010-07-16 | Hydra Biosciences Inc | Compositions useful for treating disorders related to TRPA1 |
US8575178B2 (en) | 2009-03-23 | 2013-11-05 | Glenmark Pharmaceuticals S.A. | Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators |
WO2010109329A1 (en) | 2009-03-23 | 2010-09-30 | Glenmark Pharmaceuticals, S.A. | Furopyrimidinedione derivatives as trpa1 modulators |
US8623880B2 (en) * | 2009-03-23 | 2014-01-07 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
WO2010132838A1 (en) | 2009-05-14 | 2010-11-18 | Hydra Biosciences, Inc. | Compounds useful for treating disorders related to trpa1 |
WO2011114184A1 (en) | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
WO2011132017A1 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators |
UA109916C2 (uk) | 2010-12-20 | 2015-10-26 | Гленмарк Фармасьютікалс С.А. | 2-аміно-4-арилтіазольні сполуки як антагоністи trра1 |
-
2011
- 2011-12-15 UA UAA201306497A patent/UA109916C2/uk unknown
- 2011-12-15 SG SG2013046073A patent/SG191173A1/en unknown
- 2011-12-15 CN CN201180059690.2A patent/CN103261201B/zh not_active Expired - Fee Related
- 2011-12-15 PE PE2013001454A patent/PE20140234A1/es not_active Application Discontinuation
- 2011-12-15 KR KR1020137014826A patent/KR101591153B1/ko not_active IP Right Cessation
- 2011-12-15 EP EP11813377.6A patent/EP2655377B1/en not_active Not-in-force
- 2011-12-15 JP JP2013545528A patent/JP5694560B2/ja not_active Expired - Fee Related
- 2011-12-15 AP AP2013006906A patent/AP3391A/xx active
- 2011-12-15 BR BR112013014692A patent/BR112013014692A2/pt not_active IP Right Cessation
- 2011-12-15 MX MX2013006634A patent/MX336549B/es unknown
- 2011-12-15 CA CA2820448A patent/CA2820448A1/en not_active Abandoned
- 2011-12-15 MY MYPI2013002240A patent/MY159059A/en unknown
- 2011-12-15 WO PCT/IB2011/003224 patent/WO2012085662A1/en active Application Filing
- 2011-12-15 AU AU2011346763A patent/AU2011346763B2/en not_active Ceased
- 2011-12-15 US US13/327,128 patent/US8592398B2/en not_active Expired - Fee Related
- 2011-12-15 EA EA201390947A patent/EA023141B1/ru not_active IP Right Cessation
- 2011-12-15 AR ARP110104687A patent/AR084294A1/es unknown
- 2011-12-19 TW TW100147051A patent/TWI515199B/zh not_active IP Right Cessation
-
2013
- 2013-06-19 CL CL2013001810A patent/CL2013001810A1/es unknown
- 2013-10-21 US US14/058,536 patent/US9073955B2/en not_active Expired - Fee Related
- 2013-10-21 US US14/058,509 patent/US8889862B2/en not_active Expired - Fee Related
-
2014
- 2014-04-30 HK HK14104181.5A patent/HK1191008A1/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010109287A1 (en) * | 2009-03-23 | 2010-09-30 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as trpa1 modulators |
WO2010125469A1 (en) * | 2009-04-29 | 2010-11-04 | Glenmark Pharmaceuticals, S.A. | Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181788T1 (hr) | Supstituirani spojevi piridinon-piridinil | |
AP3391A (en) | 2-Amino-4-arylthiazole compounds as TROA1 antagonists | |
EP2627178A4 (en) | QUINAZOLINONE-LIKE COMPOUNDS AS CRTH2 ANTAGONISTS | |
EP2590647A4 (en) | PRO-NEUROGENIC COMPOUNDS | |
GB201008134D0 (en) | Compounds | |
GB201015949D0 (en) | Compounds | |
EP2605658A4 (en) | SPIROXAZOLIDINONVERBINDUNGEN | |
GB201007347D0 (en) | Compounds | |
EP2649050A4 (en) | LINKS | |
HK1175171A1 (en) | Compounds as bradykinin b1 antagonists b1 | |
GB201002563D0 (en) | Compounds | |
GB201008209D0 (en) | Compounds | |
GB201001688D0 (en) | Compounds | |
GB201002216D0 (en) | Compounds | |
GB201015537D0 (en) | Compounds | |
GB201008210D0 (en) | Compounds | |
GB201001796D0 (en) | Compounds | |
HK1200443A1 (en) | Compounds as bradykinin b1 antagonists b1 | |
GB201019227D0 (en) | Compounds | |
GB201015757D0 (en) | Compounds | |
GB201015145D0 (en) | Compounds | |
GB201014392D0 (en) | Compounds | |
GB201014052D0 (en) | Compounds | |
GB201013507D0 (en) | Compounds | |
GB201013508D0 (en) | Compounds |